Viatris Inc
General
Total Cases34
Active Cases5
Patents15
Ratings
Experience
Grade
Trend
DCT
L5
D
PTAB
L5
A
CAFC
L5
A
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 11/08/24 | NOTICE OF SERVICE of Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds Notice Pursuant to 35 U.S.C. § 282 filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 11/08/2024) | |
| 11/08/24 | MEMORANDUM ORDER: The Daubert Motions (D.I. 1555 , 1559 ) are DENIED without prejudice to any specific objections at trial. (See Memorandum Order for further details). Signed by Judge Richard G. Andrews on 11/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA (aas) (Entered: 11/08/2024) | |
| 11/08/24 | REDACTED VERSION of [341] Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/8/2024 (nms). (Entered: 11/08/2024) | |
| 11/07/24 | REDACTED VERSION of [349] Declaration, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/7/2024 (nms). (Entered: 11/07/2024) | |
| 11/07/24 | SECOND REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [341] . (nms) (Entered: 11/07/2024) | |
| 11/07/24 | SECOND REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [349] . (nms) (Entered: 11/07/2024) | |
| 11/04/24 | ORAL ORDER: The redacted filings (D.I. [367] , [369] ) are REJECTED because parts of them are redacted in their entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filings are DUE within five business days. Ordered by Judge Richard G. Andrews on 11/4/2024. (nms) (Entered: 11/04/2024) | |
| 11/04/24 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [341] . (nms) (Entered: 11/04/2024) | |
| 11/04/24 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [349] (nms) (Entered: 11/04/2024) | |
| 11/03/24 | REDACTED VERSION of [346] Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/4/2024 (nms). (Entered: 11/03/2024) |